Volume 27, Issue 5 (7-2020)                   RJMS 2020, 27(5): 188-196 | Back to browse issues page

Research code: IR.ARAKMU.REC.1397.89
Ethics code: IR.ARAKMU.REC.1397.89
Clinical trials code: IRCT20141209020258N126

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Sofian M, jafari R, Ghaznavi-Rad E, Ramezani A, zarinfar N, mohaghegh P. Ampicillin-sulbactam base compared Colistin Base for the treatment of acintobacter resistant to carbapenems in ventilator associated pneumonia. RJMS 2020; 27 (5) :188-196
URL: http://rjms.iums.ac.ir/article-1-6198-en.html
, Department of community Medicine, School of Medicine, Arak University of Medical sciences, Arak, Iran , pmohaghegh@arakmu.ac.ir
Abstract:   (2727 Views)
Background: Acinetobacter baumannii (A.  baumanni) is one of the most important pathogens of Ventilator- associated Pneumonia in hospitals. Ventilator-associated pneumonia usually develops after more than 48 hours of tracheal intubation and mechanical ventilation. Prevalence of Multidrug-resistant (MDR) in Acinetobacter baumannii species is increasing. This organism can cause severe infections in hospital settings, especially in the ICU. In the past, carbapenems such as meropenem and imipenem have been used as the drug of choice in the treatment of multidrug-resistant Acinetobacter infections. Carbapenem resistance is currently increasing. Despite numerous studies to treat ventilator-associated pneumonia caused by Carbapenem- resistant A.  baumanni, the best drug choice for the treatment of this pneumonia remains unclear. Although some studies suggest Colistin as a first-line drug choice for critically ill patients with ventilator-associated pneumonia, the results of a systematic review study in 2017 showed that monotherapy with sulbactam in the treatment of pneumonia caused by drug-resistant Acinetobacter is preferable to treatment with intravenous colistin. Researchers have recommended clinical trials to confirm the findings in this pneumonia. Therefore, the purpose of this study was to compare colistin based vs. Ampicillin-Sulbactam based therapy in carbapenem-resistant A.  baumanni ventilator- associated pneumonia.
Methods: In this double-blind clinical trial study, 43 patients with ventilator-associated pneumonia who were admitted to the ICU of Valiasr Hospital in Arak, Iran, were included in the study and were assessed in two groups: colistin based vs. Ampicillin-Sulbactam based. Patients were evaluated at baseline and at the end of treatment for white blood cell count, ESR, and sputum culture and mortality. Inclusion criteria included age over 16 years and ventilator-induced pneumonia with carbapenem-resistant A.  baumanni. Exclusion criteria included discontinuation of treatment and patient dissatisfaction to continue the study. Lower Respiratory Secretion was collected from these patients and sent to the laboratory. Isolation of bacteria was performed according to the standard bacteriological method and then using isolated biochemical methods, the isolated bacteria were identified up to the species. E-test was used to determine the lowest growth inhibitory concentration (MIC) to colistin and ampicillin sulbactam. The sample size was 33 patients in each group. There were 33 patients in the Colistin group. In the ampicillin-sulbactam group, 10 patients and 20 laboratory samples with ampicillin-sulbactam discs were also performed by antibiogram method. Laboratory sputum culture was used because antibiotic resistance was observed in the first 10 patients in the ampicillin-sulbactam group and there was no complete recovery and therefore due to concern for the lives of patients; The rest of the samples were performed in vitro. Patients were evaluated at the beginning and end of treatment on day 14. It should be noted that in order to double-blinded study, the patient and the data analyzer did not know about grouping. Data were analyzed by SPSS 20 software using descriptive statistics, t-test and chi-square. The normality of quantitative data distribution was checked by Kolmogorov-Smirnov test. The code of ethics of this dissertation was IR.ARAKMU.REC.1397.89. The registration code in Iran Clinical Trial Center for the above dissertation was IRCT20141209020258N126.
Results: In this double-blind clinical trial study, 33 patients in the colistin group and 10 patients and 20 sputum culture samples in the ampicillin-sulbactam group were studied. The mean ± standard deviation of age of 43 patients was 48.23±16.85 years. The minimum age was 19 years and the maximum age was 85 years. In the cholistin + carbapenem group, out of 33 patients who were initially admitted to the study, 3 died before the end of the study and in the ampicillin-sulbactam group, out of 10 patients admitted to the study, 2 died before the end of the study.
 The number of WBC and the rate of ESR in the colistin + carbapenem group were decreased significantly (p<0.05) and 23 cases of sputum culture were negative for acinetobacter at the end of the study. in the colistin based group on day 14 of treatment, only 2 patients had higher than normal WBC counts and 24 cases had normalized chest X-rays. In the ampi-sulbactam+carbapenem group, at the end of treatment, 3 patients had normal WBC counts. Only one sputum culture was negative and 1 case had normal chest x-ray at the end of study. In 20 sputum culture samples that were examined in vitro, only two samples were sensitive to ampicillin-sulbactam and 18 cases were resistant to ampicillin-sulbactam.
Conclusion: The use of colistin+carbapenem improves clinical and laboratory response of patients. Therefore colistin-based therapy for the treatment of Carbapenem- resistant A.  baumanni ventilator-associated pneumonia is recommended..
Full-Text [PDF 732 kb]   (631 Downloads)    
Type of Study: Research | Subject: Infectious Disease

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Razi Journal of Medical Sciences

Designed & Developed by : Yektaweb